Nippon Life Global Investors Americas’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-880
Closed -$925K 112
2024
Q3
$925K Buy
880
+40
+5% +$44.5K 0.04% 95
2024
Q2
$883K Sell
840
-230
-21% -$223K 0.04% 89
2024
Q1
$1.03M Sell
1,070
-60
-5% -$57.1K 0.05% 87
2023
Q4
$992K Sell
1,130
-360
-24% -$296K 0.06% 110
2023
Q3
$1.23M Hold
1,490
0.08% 104
2023
Q2
$1.07M Hold
1,490
0.07% 109
2023
Q1
$1.22M Sell
1,490
-430
-22% -$324K 0.08% 105
2022
Q4
$1.39M Sell
1,920
-29,000
-94% -$21.4M 0.09% 102
2022
Q3
$21.3M Buy
30,920
+1,320
+4% +$831K 1.5% 20
2022
Q2
$17.5M Sell
29,600
-1,710
-5% -$1.11M 1.13% 27
2022
Q1
$21.9M Sell
31,310
-12,720
-29% -$8.05M 1.17% 22
2021
Q4
$27.8M Buy
44,030
+3,160
+8% +$1.94M 1.31% 15
2021
Q3
$24.7M Buy
40,870
+32,450
+385% +$20.1M 1.29% 16
2021
Q2
$4.7M Hold
8,420
0.23% 105
2021
Q1
$3.98M Hold
8,420
0.22% 107
2020
Q4
$4.07M Hold
8,420
0.24% 94
2020
Q3
$4.71M Hold
8,420
0.31% 80
2020
Q2
$5.25M Sell
8,420
-130
-2% -$73.8K 0.38% 68
2020
Q1
$4.18M Sell
8,550
-44,420
-84% -$18.3M 0.37% 71
2019
Q4
$19.9M Buy
52,970
+4,850
+10% +$1.63M 1.35% 18
2019
Q3
$13.3M Buy
48,120
+18,320
+61% +$5.42M 0.98% 32
2019
Q2
$9.33M Buy
29,800
+22,940
+334% +$7.64M 0.71% 50
2019
Q1
$2.82M Sell
6,860
-32,220
-82% -$13.3M 0.23% 107
2018
Q4
$14.6M Sell
39,080
-60
-0.2% -$22K 1.26% 25
2018
Q3
$15.8M Buy
39,140
+5,220
+15% +$1.99M 1.21% 27
2018
Q2
$11.7M Sell
33,920
-4,130
-11% -$1.29M 0.93% 36
2018
Q1
$13.1M Buy
38,050
+1,510
+4% +$525K 1.08% 28
2017
Q4
$13.7M Buy
36,540
+7,610
+26% +$3.08M 1.1% 30
2017
Q3
$12.9M Sell
28,930
-4,550
-14% -$2.17M 1.1% 32
2017
Q2
$16.4M Buy
33,480
+27,790
+488% +$12.2M 1.41% 17
2017
Q1
$2.21M Buy
+5,690
New +$2.11M 0.2% 113
2014
Q1
Sell
-5,430
Closed -$1.5M 167
2013
Q4
$1.5M Buy
+5,430
New +$1.56M 0.15% 130

Other funds holding REGN

Nippon Life Global Investors Americas's REGN Position: Q4 2024 in Review

Nippon Life Global Investors Americas sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 880 shares — an estimated $925K sold.

Nippon Life Global Investors Americas first reported a position in REGN in Q4 2013 and held it in 32 quarters. The position peaked at $27.8M in Q4 2021. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Nippon Life Global Investors Americas reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nippon Life Global Investors Americas sold 880 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $925K.
  • Nippon Life Global Investors Americas first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 32 quarters.
  • Nippon Life Global Investors Americas's Regeneron Pharmaceuticals position peaked at $27.8M in Q4 2021.
  • 1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Nippon Life Global Investors Americas's 13F filing for Q4 2024, filed 14 Feb 2025.